Synovial Fluid Biomarker Detection for Accurate Joint Infection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for joint infections, particularly in total joint replacements, are inaccurate and lack consensus, leading to misdiagnosis and increased medical costs, with potential catastrophic consequences.
Innovation Solution
A system for diagnosing joint infection by detecting specific biomarkers in synovial fluid using a first detection reagent and an internal control detector reagent, achieving at least 90% accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood test is performed for joint infection diagnosis, then general response can be obtained, but sensitivity is less than 80% and specificity is less than 70%
Solution Approach 1:
The invention extracts and detects specific biomarkers (proteins, peptides, or nucleic acids) directly from synovial fluid or periprosthetic fluid, rather than performing general blood tests. This extraction of specific diagnostic targets from the relevant fluid source enables significantly improved sensitivity and specificity for joint infection diagnosis.
Solution Approach 2:
The invention uses specific biomarkers as intermediaries to indicate the presence of joint infection. These biomarkers serve as mediators between the infection state and the diagnostic test, providing more accurate information than general blood tests by specifically reflecting the local joint environment.
2Loss of information
If joint fluid analysis is performed, then diagnostic information is obtained, but there is no consensus on which tests are most useful
Solution Approach 1:
The invention segments the diagnostic approach by focusing on specific, identified biomarkers (such as proteins, peptides, or nucleic acids) rather than attempting to analyze all possible components of synovial fluid. This segmentation into targeted biomarker detection simplifies the diagnostic process while maintaining comprehensive diagnostic information.
Solution Approach 2:
The invention changes the diagnostic parameter from general synovial fluid analysis to specific biomarker detection. By identifying and measuring particular proteins, peptides, or nucleic acids associated with joint infection, the invention provides a standardized, consensus-based approach that reduces complexity while preserving diagnostic information.
3Productivity
If current diagnostic methods are used for total joint replacements, then general screening is possible, but misdiagnosis occurs frequently leading to increased medical costs
Solution Approach 1:
The invention replaces conventional mechanical or general chemical diagnostic methods with specific biomarker detection techniques. This substitution enables both rapid screening and accurate diagnosis by targeting specific molecular indicators of joint infection, thereby improving both productivity and reliability simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides accurate diagnosis of joint infections with high sensitivity and specificity, enabling effective treatment and reducing the risk of misdiagnosis.
Implementation Method 1
a first detection reagent that detects the presence of the biomarker for joint infection in synovial fluid, wherein the first detector reagent specifically binds the biomarker
Implementation Method 2
an internal control detector reagent for verification of synovial fluid, wherein the internal control detector reagent specifically binds a marker of synovial fluid
Data Source
AI summary
The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.